Acetazolamide for Treatment Resistant Schizophrenia

Schizophrenia Clinical Trial

— APTS  

Official title:

A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04887792
• Other study ID #: STUDY20010237
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 1, 2022
• Est. completion date: June 30, 2025

Study information

• Verified date: January 2024
• Source: University of Pittsburgh
• Contact: Vishwajit L Nimgaonkar, M.D., Ph.D.
• Phone: 412-246-6356
• Email: vishwajitNL[@]upmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

Description:

Schizophrenia (SZ) afflicts over 21 million people worldwide. Persons with SZ have a 10% suicide rate and their lifespan is curtailed by over 25 years. There is an urgent need for efficacious antipsychotic drugs (APDs), particularly, second line drugs, because only 30-40% of APD-treated patients attain remission and 30% of patients show little or no response. Currently, Clozapine is the only reliable second line APD, but it can cause serious blood dyscrasias. To fill the void, the investigators have conducted systematic reviews of prior data and in silico searches. In a prior double-blind crossover randomized placebo-controlled trial (RCT), adjunctive Acetazolamide (ACZ) caused ~20% improvement in positive and negative symptom scores when added to APDs among partially-responsive patients with SZ (ACZ 2G/day). No patients dropped out. The RCT is supported by several other open trials. ACZ also reduces weight, thus it could combat weight gain, a common APD side effect. Independently, our systematic in silico strategy based on protein networks and gene expression profiles also identified Acetazolamide (ACZ) as a repurposable drug for SZ.

ACZ crosses the blood-brain barrier. It is used to treat CNS diseases such as refractory seizures and idiopathic intracranial hypertension. Used for over 50 years, its side effects (SE) and adverse effects (AE) are well known and are manageable. It is a potent, specific inhibitor of carbonic anhydrase (CA), which catalyzes the conversion of CO2 to HCO3- and H+. CA is localized to pre-synaptic terminals and glial cells. It modulates GABAergic excitation, long-term synaptic transformation, attentional gating of memory storage and cerebrospinal fluid formation. Post-mortem brain and serological studies show raised CA levels in patients with psychotic/mood disorders. Several APDs also inhibit CA. The investigators thus postulate brain CA inhibition as the therapeutic target for ACZ in SZ.

The investigators propose a double-blind, crossover RCT for SZ using adjunctive ACZ. To maximize the risk/benefit ratio, the investigators will enroll inpatients and outpatients with treatment resistant SZ (trSZ) who meet defined criteria (N=60 RCT completers). ACZ or placebo will be added to prescribed APDs for 8 weeks utilizing the Sequential Parallel Comparison Design to maximize power. The investigators have extensive experience with RCTs. The investigators will ensure timely recruitment by approaching a large group of patients we serve, across 2 sites. If ACZ is beneficial, in future studies the investigators will pursue its implementation for trSZ, and seek variables associated with treatment response.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: June 30, 2025
• Est. primary completion date: January 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Written informed consent.

• Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).

• PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.

• Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study.

• Not participating in another randomized controlled clinical trial (RCT).

Exclusion Criteria:

• Substance abuse in the past month/dependence past 6 months, (except nicotine).

• History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.

• Pregnancy.

• Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.

• Current or prior treatment with ACZ or history of hypersensitivity to ACZ.

• Intellectual disability as defined in DSM 5.

Related Conditions & MeSH terms

• Mood Disorders
• Psychotic Disorders
• Schizo Affective Disorder
• Schizophrenia

Intervention

Drug:
• Acetazolamide
ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
• Placebo
Identical gelatin capsules will be prepared by filling with inert excipients.

Locations

Country	Name	City	State
India	St John's Medical College Hospital	Bangalore
United States	University of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Vishwajit Nimgaonkar, MD PhD	Stanley Medical Research Institute

Countries where clinical trial is conducted

United States,  India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in positive symptoms	Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 7 Items, (minimum score = 7, maximum score = 49)	24 weeks
Secondary	Clinical Severity	Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 30 Items, (minimum score = 7, maximum score = 210)	24 weeks
Secondary	Clinical Severity	Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 7 Items, (minimum score = 7, maximum score = 49)	24 weeks
Secondary	Cognition	Trail Making Test (TMT) 86: This test estimates attention, working memory and executive function.	24 weeks
Secondary	Clinical Severity	"Clinical Global Impression - Severity" (CGI-S). The CGI-S is a 7-point scale that rates the severity of the patient's illness at the time of assessment. The minimum score is 1 and the maximum score is 100. Scores which are lower in value indicate greater severity of illness. Higher scores indicate less severe illness.	24 weeks
Secondary	Social Function	"Sheehan's Disability Scale" (SDS). The SDS is a self-report is a self-report tool that assesses functional impairment in work/school, social and family life with a 10-point visual analogue scale. The minimum score is 0 and the maximum score is 10. Scores which are lower in value indicate better outcomes with less disability. Higher scores indicate more severe illness with greater disability.	24 weeks
Secondary	Global Assessment of Function	"Global Assessment of Function" (GAF). The GAF is an assessor reporting tool that assesses level of functioning on a 1 to 100 point scale. The minimum score is 1 and the maximum score is 100. Scores which are higher in value indicate better outcomes with less disability. Lower scores indicate more severe illness with greater disability.	24 weeks
Secondary	Measure of satisfaction with one's Quality of Life (Quality of Life Scale/QOLS)	The QOLS was originally a 15-item instrument that measured five conceptual domains of quality of life: material and physical well-being, relationships with other people, social, community and civic activities, personal development and fulfillment, and recreation. After descriptive research that queried persons with chronic illness on their perceptions of quality of life, the instrument was expanded to include one more item: Independence, the ability to do for yourself. Thus, the QOLS in its present format contains 16 items.; The QOLS is scored by adding up the score on each item to yield a total score for the instrument. Scores can range from 16 to 112. The QOLS scores are summed so that a higher score indicates higher quality of life. Average total score for healthy populations is about 90.	24 weeks
Secondary	Socio-Economic Status	We will use a composite measure of educational attainment and pretax family (household) income based on the Hollingshead Redlich 4-factor index.; The Hollingshead Four Factor Index of Socioeconomic Status is a survey designed to measure social status of an individual based on four domains: marital status, retired/employed status, educational attainment, and occupational prestige. The participant's education code is obtained education code is rated on a 7-point scale that lists highest grade completed. The participant's occupational code is rated on a 9-point scale.; SES=0.5X education score+0.3Xincome score+ 0.3X occupation score.	24 weeks
Secondary	Side Effects	We will make a list of side effects for CGY noted in the Drug Formulary. This list will be a comprehensive listing of possible side effects by body system, grading both the frequency and severity of the symptoms.; Frequency (days per week): Severity: 0 = Absent; = 1-2 days 1 = mild, does not interfere with functioning; = 3-4 days 2 = moderate, some interference with functioning; = 5-7 days 3 = severe, functioning is significantly impaired; Frequency scores can range from 0 to 3, with higher scores equaling higher frequency.; Severity scores can range from 1 to 3, with higher scores equaling greater severity.	24 weeks